Studies
The CTN+ supports clinical trials to find new ways to prevent, treat and manage HIV and other STBBIs, prioritizing a community-based approach of the highest scientific and ethical standards.
-
CTN 161: Simplified Protease Inhibitor Trial (SPRINT)
An International, Open-Label, Randomized, Multicentre Study to Evaluate the Antiviral Effect, Tolerability, Safety and Pharmacokinetics of Fortovase (saquinavir SGC) and Norvir (ritonavir) QD vs. Crixivan (indinavir) and Norvir (ritonavir) BID in HIV-Infected Patients
-
CTN 160: The Double Non-Nucleoside Study (2NN Study)
An Open-Label, Comparative Study to Evaluate the Antiviral Efficacy and Safety of Nevirapine and Efavirenz or Both Drugs Combined in Combination with d4T and 3TC. (The 2NN or Double Non-Nucleoside Study): Trial results
-
CTN 158: The CpG ODN 7909 as an Adjuvant and Immune Modulator
Phase I Safety and Immunogenicity Study of CpG ODN 7909 as an Immune Modulator and Adjuvant to Engerix®-B Vaccine in Haart-Treated, HIV-Positive Patients: Trial results
-
CTN 151: Multiple Drug Rescue Therapy
A Pilot Study Comparing Two Modalities of Multiple Drug Rescue Therapy (MDRT) among Pre-Treated, HIV-1 Infected Individuals – Full versus Sensitivity-Based MDRT Protocol: Trial results
-
CTN 149: Two PIs versus Efavirenz, with Two NRTIs
Open-Label, Randomized, Multicenter Study to Evaluate Fortovase® (Saquinavir SGC) QD, Norvir® (Ritonavir) QD plus Two NRTIs Vs. SustivaTM (Efavirenz) QD plus Two NRTIs in HIV-Infected Patients: Trial results
-
CTN 147: Early versus delayed pneumococcal vaccination
A pilot study assessing the efficacy of pneumococcal vaccine in HIV patients: delayed versus immediate immunization: Trial results
-
CTN 145: rIL-2 to slow progression of HIV (SILCAAT)
A Phase III, multicentre, randomized study of the biological and clinical efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with low CD4+ counts under active antiretroviral therapy(SILCAAT): Trial results
-
CTN 143: Twice Daily Indinavir plus Ritonavir
An Open-Label, Randomized, 48-Week Study to Compare the Safety, Tolerability, and Surrogate Marker Activity of an Indinavir Sulfate (800 mg q8h) Regimen versus BID Indinavir Sulfate (800 mg q12h) plus Ritonavir (100 mg q12h) Regimen in HIV-Infected Individuals Having Previously Achieved Viral Load Suppression below the Limit of Detection with a Triple Antiretroviral Treatment Regimen…
-
CTN 131: ddI, d4T and DMP with or without Hydroxyurea (3D Study)
A Randomized Placebo-Controlled Study of the Safety and Efficacy of Efavirenz (DMP), Didanosine and Stavudine in Combination with or without Hydroxyurea in Antiretroviral-Naïve or -Experienced, HIV-Infected Patients:
-
CTN 119: Abacavir plus Amprenavir versus Nelfinavir
A Comparison of a Four-drug Regimen Comprised of 141W94, Abacavir (1592U89), and Combivir with a Three-drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naïve, HIV-Infected Subjects. (Protocol 528/270 [NZTA4002])
-
CTN 118: Once Daily ADV plus ddI plus 3TC plus NVP (QD Study)
A Comparative Study of the Antiviral Effect of a Two or Three Times Daily Triple-Drug Regimen (Indinavir, Nelfinavir or Saquinavir [SGC], Lamivudine plus Zidovudine or Stavudine) against a Once Daily Regimen including Adefovir, Didanosine, Lamivudine and Nevirapine: Trial results
-
CTN 117: Intermittent Rifabutin for MAC and TB
A Pharmacokinetic Assessment of Intermittent Rifabutin Dosing Regimens in the Setting of Protease Inhibitor Therapy with a Combination of Ritonavir and Saquinavir in HIV-Infected Patients: Trial results
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.
Learn More